目的：观察玻璃体腔注射雷珠单抗治疗湿性年龄相关性黄斑变性(ARMD)的疗效和对患眼血流动力学的影响，以期为临床诊疗提供参考。

方法：分析2015-01/2017-01在我院接受治疗的湿性ARMD患者41例41眼的临床资料。所有患者均在同一组医师指导下接受玻璃体腔注射雷珠单抗治疗。治疗后1mo评估疗效和眼部血流动力学及炎症指标。

结果：治疗前后患者视力比较差异有统计学意义(t=25.460，P<0.01)，同时黄斑中心凹厚度显著降低，差异有统计学意义(239.1±51.9 vs 452.9±69.8μm； t=15.740，P<0.01)。治疗期间未出现严重并发症。治疗后，患者房水TNF-α(13.1±4.1 vs 16.1±3.5ng/L； t=3.563，P<0.01)及IL-6(12.1±1.9 vs 13.8±2.5ng/L； t=3.467，P<0.01)水平显著降低，差异具有统计学意义(P<0.01)。治疗后患者眼动脉和视网膜中央动脉的收缩期峰值流速及舒张末期血流速度均未见明显改变，差异无统计学意义(P>0.05)。

结论：玻璃体腔注射雷珠单抗治疗湿性ARMD患者效果显著，且可同时改善眼部炎症反应，未发现其对眼部血流动力学造成明显影响。

METHODS: Clinical data of patients with wet age-related macular degeneration received treatment of ranibizumab at our hospital from 2015 to 2017 were analyzed. At 1mo after treatment, the clinical efficacy, ocular hemodynamics and ocular inflammation were evaluated.

RESULTS: A total of 41 patients were analyzed. After treatment, patients got significantly increased in LogMAR(0.651±0.067 vs 0.321±0.049; t=25.460, P<0.01)and decreased in central foveal thickness(239.1±51.9μm vs 452.9±69.8μm; t=15.740, P<0.01). There was no serious complication during treatment period. After treatment, the levels of TNF-α(13.1±4.1ng/L vs 16.1±3.5ng/L; t=3.563, P<0.01)and IL-6(12.1±1.9ng/L vs 13.8±2.5ng/L; t=3.467, P<0.01)in aqueous fluid decreased significantly. There was no significantly changes of blood flow volume of central retinal artery and ophthalmic artery at peak systolic velocity and end diastolic velocity before and after treatment(P>0.05).

CONCLUSION: In the treatment of wet age-related macular degeneration, the ranibizumab shows a good therapeutic effect without serious adverse drug reactions.